Trials / Completed
CompletedNCT06740474
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Healthy Participants
A Phase 1a, Blinded, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Single- and Multiple-Ascending Doses of ABI-6250 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Assembly Biosciences · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This study is designed to assess safety, tolerability, and pharmacokinetics of single ascending doses (SAD) and multiple-ascending doses (MAD) of ABI-6250 in healthy participants. Effect of food will also be evaluated in Part A.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABI-6250 | Single dose (SAD) or once or twice daily dosing over 10 days (MAD) |
| DRUG | Placebo | Single dose (SAD) or once or twice daily dosing over 10 days (MAD) |
Timeline
- Start date
- 2025-01-31
- Primary completion
- 2025-07-08
- Completion
- 2025-07-08
- First posted
- 2024-12-18
- Last updated
- 2025-12-04
Locations
1 site across 1 country: New Zealand
Source: ClinicalTrials.gov record NCT06740474. Inclusion in this directory is not an endorsement.